Shree Ganesh Remedies reported Q4FY26 revenue of ₹33.20 crore, up 36% YoY, while PAT declined 5% to ₹6.27 crore.
FY26 was a consolidation year with revenue flat at ₹109.29 crore and PAT down 23% to ₹17.77 crore amid challenging market conditions.
The company completed pilot trials for CRAMS projects in agrochemicals, pharmaceuticals, and electronics, with commercial production expected after approvals.
Block 7 expansion remains on track for Q2FY27 commissioning to support niche molecule pipeline and future growth.